GLP-1 Agonists and Weight Management - Core - CDEP

The GLP-1 agonists, Liraglutide (Saxenda®), Semaglutide (Wegovy®) and Tirzepatide (Mounjaro®), have been shown to be effective in supporting weight loss in eligible people living with obesity, alongside diet and exercise interventions. This topic is designed to give you an overview of obesity management and where GLP-1 agonists therapy sits within the wider NHS weight management strategies to support people living with obesity. A key focus is on the use of Tirzepatide to support the phased roll-out in Primary Care as per NICE TA1026's implementation plan. TOPIC TIPS...
You do not have to complete the topic in one go... CDEP is designed to be done in 'bite-sized chunks' fitting into your busy life!
This topic generally takes around 30 - 60 minutes to complete depending on your chosen CDEP level - although this may differ from person to person.
There are a number of sections (competencies) within this topic, each with its own set of resources that may be useful to review should you require further support.
However, undertaking the section itself is part of the learning process and will confirm or improve your current level of knowledge around that specific section, so why not jump straight in and have a go...